Thromboembolic events in COVID-19 ambulatory patients: An observational study about incidence, and thromboprophylaxis outcomes
Introduction There are no clear data about the incidence and the prophylactic strategies of arterial and venous thromboembolic events (TE) in COVID-19 ambulatory patients. Thus, we conducted this study to analyze thromboembolic complications in this setting and to assess thromboprophylaxis managemen...
Gespeichert in:
| Veröffentlicht in: | PloS one 2022-08, Vol.17 (8), p.e0270195-e0270195 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0270195 |
|---|---|
| container_issue | 8 |
| container_start_page | e0270195 |
| container_title | PloS one |
| container_volume | 17 |
| creator | Hammami, Rania Jdidi, Jihen Chakroun, Olfa Issaoui, Fadhila Ktata, Nouha Maamri, Hanen Baklouti, Mouna Bahloul, Amine Gargouri, Rania Nasri, Abdennour Msaad, Sameh Kammoun, Samy Kammoun, Samir Rejab, Imen Ben Charfeddine, Selma Abid, Leila |
| description | Introduction There are no clear data about the incidence and the prophylactic strategies of arterial and venous thromboembolic events (TE) in COVID-19 ambulatory patients. Thus, we conducted this study to analyze thromboembolic complications in this setting and to assess thromboprophylaxis management and outcomes in the real life. Patients and methods This is an observational study including Covid-19 ambulatory patients. We assessed incidence of venous and arterial TE events as well as thromboprophylaxis outcomes and hemorrhagic complications. We defined high risk thrombo-embolic factor according to the Belgian guidelines which are the only guidelines that described thromboprophylaxis in COVID-19 ambulatory patients. Results We included 2089 patients with a mean age of 43±16 years. The incidence of 30 days venous and arterial TE complications in our cohort was 1%. Venous thromboembolic complications occurred in 0.8% and arterial thromboembolic complications occurred in 0.3%.We noted at least one high-risk TE factor in 18.5% of patients but thromboprophylaxis was prescribed in 22.5% of the cases, LMWH in 18.1%, and Rivaroxaban in 3.7%. Hemorrhagic events occurred in eight patients (0.3%): five patients showed minor hemorrhagic events and three patients showed major ones (0.14%). Conclusions Our study showed that the incidence of thromboembolic complications is very low in COVID-19 ambulatory patients. Paradoxically, there is an over prescription of thrombo-prophylaxis in this population. |
| doi_str_mv | 10.1371/journal.pone.0270195 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2698609694</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A712539758</galeid><doaj_id>oai_doaj_org_article_21a10e9b3ed0405cacbbaf0f53651164</doaj_id><sourcerecordid>A712539758</sourcerecordid><originalsourceid>FETCH-LOGICAL-c669t-399054527ba84a290119e9455ae0c12dc1aa5f1f88d36c135ce3df5de300cea03</originalsourceid><addsrcrecordid>eNqNk9-L1DAQx4so3nn6HwgWBFFw16Rpso0PwrL-WjhY0PNewzSd7mZpm17SLrcv_u2mbpWr3IOEkDDzme8kw0wUPadkTtmCvtvb3jVQzVvb4JwkC0IlfxCdU8mSmUgIe3jnfhY98X5PCGeZEI-jM8ZlwiUj59HPq52zdW4x7MroGA_YdD42TbzaXK8_zqiMoc77CjrrjnELnRn87-NlE9vcozsEiw3PiH3XF8cYctt3IVqbAhuNb2Noirg7pWidbXfHCm6NjwOlbY3-afSohMrjs_G8iH58_nS1-jq73HxZr5aXMy2E7GZMSsJTnixyyFJIJKFUokw5BySaJoWmALykZZYVTGjKuEZWlLxARohGIOwienHSbSvr1Vg6rxIhM0GkkGkg1ieisLBXrTM1uKOyYNRvg3VbBa4zukKVUKAEZc6wICnhGnSeQ0lKzgSnVAxaH8ZsfV5joUPJHFQT0amnMTu1tQclGU9INgi8HgWcvenRd6o2XmNVQYO2H9_NiKAioC__Qe__3UhtIXzANKUNefUgqpYLmnAmFzwL1PweKqwCa6NDn5Um2CcBbyYBgenwtttC771af__2_-zmesq-usPuEKpu523VD73mp2B6ArWz3jss_xaZEjWMyZ9qqGFM1Dgm7BeoiwT_</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2698609694</pqid></control><display><type>article</type><title>Thromboembolic events in COVID-19 ambulatory patients: An observational study about incidence, and thromboprophylaxis outcomes</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Public Library of Science (PLoS)</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Hammami, Rania ; Jdidi, Jihen ; Chakroun, Olfa ; Issaoui, Fadhila ; Ktata, Nouha ; Maamri, Hanen ; Baklouti, Mouna ; Bahloul, Amine ; Gargouri, Rania ; Nasri, Abdennour ; Msaad, Sameh ; Kammoun, Samy ; Kammoun, Samir ; Rejab, Imen Ben ; Charfeddine, Selma ; Abid, Leila</creator><contributor>Ai, Tomohiko</contributor><creatorcontrib>Hammami, Rania ; Jdidi, Jihen ; Chakroun, Olfa ; Issaoui, Fadhila ; Ktata, Nouha ; Maamri, Hanen ; Baklouti, Mouna ; Bahloul, Amine ; Gargouri, Rania ; Nasri, Abdennour ; Msaad, Sameh ; Kammoun, Samy ; Kammoun, Samir ; Rejab, Imen Ben ; Charfeddine, Selma ; Abid, Leila ; Ai, Tomohiko</creatorcontrib><description>Introduction There are no clear data about the incidence and the prophylactic strategies of arterial and venous thromboembolic events (TE) in COVID-19 ambulatory patients. Thus, we conducted this study to analyze thromboembolic complications in this setting and to assess thromboprophylaxis management and outcomes in the real life. Patients and methods This is an observational study including Covid-19 ambulatory patients. We assessed incidence of venous and arterial TE events as well as thromboprophylaxis outcomes and hemorrhagic complications. We defined high risk thrombo-embolic factor according to the Belgian guidelines which are the only guidelines that described thromboprophylaxis in COVID-19 ambulatory patients. Results We included 2089 patients with a mean age of 43±16 years. The incidence of 30 days venous and arterial TE complications in our cohort was 1%. Venous thromboembolic complications occurred in 0.8% and arterial thromboembolic complications occurred in 0.3%.We noted at least one high-risk TE factor in 18.5% of patients but thromboprophylaxis was prescribed in 22.5% of the cases, LMWH in 18.1%, and Rivaroxaban in 3.7%. Hemorrhagic events occurred in eight patients (0.3%): five patients showed minor hemorrhagic events and three patients showed major ones (0.14%). Conclusions Our study showed that the incidence of thromboembolic complications is very low in COVID-19 ambulatory patients. Paradoxically, there is an over prescription of thrombo-prophylaxis in this population.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0270195</identifier><identifier>PMID: 35925930</identifier><language>eng</language><publisher>San Francisco: Public Library of Science</publisher><subject>Asymptomatic ; Blood clot ; Body mass index ; Cohort analysis ; Complications ; Coronaviruses ; COVID-19 ; Data collection ; Guidelines ; Health risks ; Hemorrhage ; Hospitalization ; Hospitals ; Illnesses ; Medicine and Health Sciences ; Observational studies ; Patients ; Polymerase chain reaction ; Prevention ; Prophylaxis ; Questionnaires ; Risk factors ; Sea level ; Severe acute respiratory syndrome coronavirus 2 ; Thromboembolism ; Thrombosis</subject><ispartof>PloS one, 2022-08, Vol.17 (8), p.e0270195-e0270195</ispartof><rights>COPYRIGHT 2022 Public Library of Science</rights><rights>2022 Hammami et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 Hammami et al 2022 Hammami et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c669t-399054527ba84a290119e9455ae0c12dc1aa5f1f88d36c135ce3df5de300cea03</citedby><cites>FETCH-LOGICAL-c669t-399054527ba84a290119e9455ae0c12dc1aa5f1f88d36c135ce3df5de300cea03</cites><orcidid>0000-0003-1168-6450 ; 0000-0002-9224-7080</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352084/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352084/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,2103,2929,23871,27929,27930,53796,53798</link.rule.ids></links><search><contributor>Ai, Tomohiko</contributor><creatorcontrib>Hammami, Rania</creatorcontrib><creatorcontrib>Jdidi, Jihen</creatorcontrib><creatorcontrib>Chakroun, Olfa</creatorcontrib><creatorcontrib>Issaoui, Fadhila</creatorcontrib><creatorcontrib>Ktata, Nouha</creatorcontrib><creatorcontrib>Maamri, Hanen</creatorcontrib><creatorcontrib>Baklouti, Mouna</creatorcontrib><creatorcontrib>Bahloul, Amine</creatorcontrib><creatorcontrib>Gargouri, Rania</creatorcontrib><creatorcontrib>Nasri, Abdennour</creatorcontrib><creatorcontrib>Msaad, Sameh</creatorcontrib><creatorcontrib>Kammoun, Samy</creatorcontrib><creatorcontrib>Kammoun, Samir</creatorcontrib><creatorcontrib>Rejab, Imen Ben</creatorcontrib><creatorcontrib>Charfeddine, Selma</creatorcontrib><creatorcontrib>Abid, Leila</creatorcontrib><title>Thromboembolic events in COVID-19 ambulatory patients: An observational study about incidence, and thromboprophylaxis outcomes</title><title>PloS one</title><description>Introduction There are no clear data about the incidence and the prophylactic strategies of arterial and venous thromboembolic events (TE) in COVID-19 ambulatory patients. Thus, we conducted this study to analyze thromboembolic complications in this setting and to assess thromboprophylaxis management and outcomes in the real life. Patients and methods This is an observational study including Covid-19 ambulatory patients. We assessed incidence of venous and arterial TE events as well as thromboprophylaxis outcomes and hemorrhagic complications. We defined high risk thrombo-embolic factor according to the Belgian guidelines which are the only guidelines that described thromboprophylaxis in COVID-19 ambulatory patients. Results We included 2089 patients with a mean age of 43±16 years. The incidence of 30 days venous and arterial TE complications in our cohort was 1%. Venous thromboembolic complications occurred in 0.8% and arterial thromboembolic complications occurred in 0.3%.We noted at least one high-risk TE factor in 18.5% of patients but thromboprophylaxis was prescribed in 22.5% of the cases, LMWH in 18.1%, and Rivaroxaban in 3.7%. Hemorrhagic events occurred in eight patients (0.3%): five patients showed minor hemorrhagic events and three patients showed major ones (0.14%). Conclusions Our study showed that the incidence of thromboembolic complications is very low in COVID-19 ambulatory patients. Paradoxically, there is an over prescription of thrombo-prophylaxis in this population.</description><subject>Asymptomatic</subject><subject>Blood clot</subject><subject>Body mass index</subject><subject>Cohort analysis</subject><subject>Complications</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Data collection</subject><subject>Guidelines</subject><subject>Health risks</subject><subject>Hemorrhage</subject><subject>Hospitalization</subject><subject>Hospitals</subject><subject>Illnesses</subject><subject>Medicine and Health Sciences</subject><subject>Observational studies</subject><subject>Patients</subject><subject>Polymerase chain reaction</subject><subject>Prevention</subject><subject>Prophylaxis</subject><subject>Questionnaires</subject><subject>Risk factors</subject><subject>Sea level</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Thromboembolism</subject><subject>Thrombosis</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk9-L1DAQx4so3nn6HwgWBFFw16Rpso0PwrL-WjhY0PNewzSd7mZpm17SLrcv_u2mbpWr3IOEkDDzme8kw0wUPadkTtmCvtvb3jVQzVvb4JwkC0IlfxCdU8mSmUgIe3jnfhY98X5PCGeZEI-jM8ZlwiUj59HPq52zdW4x7MroGA_YdD42TbzaXK8_zqiMoc77CjrrjnELnRn87-NlE9vcozsEiw3PiH3XF8cYctt3IVqbAhuNb2Noirg7pWidbXfHCm6NjwOlbY3-afSohMrjs_G8iH58_nS1-jq73HxZr5aXMy2E7GZMSsJTnixyyFJIJKFUokw5BySaJoWmALykZZYVTGjKuEZWlLxARohGIOwienHSbSvr1Vg6rxIhM0GkkGkg1ieisLBXrTM1uKOyYNRvg3VbBa4zukKVUKAEZc6wICnhGnSeQ0lKzgSnVAxaH8ZsfV5joUPJHFQT0amnMTu1tQclGU9INgi8HgWcvenRd6o2XmNVQYO2H9_NiKAioC__Qe__3UhtIXzANKUNefUgqpYLmnAmFzwL1PweKqwCa6NDn5Um2CcBbyYBgenwtttC771af__2_-zmesq-usPuEKpu523VD73mp2B6ArWz3jss_xaZEjWMyZ9qqGFM1Dgm7BeoiwT_</recordid><startdate>20220804</startdate><enddate>20220804</enddate><creator>Hammami, Rania</creator><creator>Jdidi, Jihen</creator><creator>Chakroun, Olfa</creator><creator>Issaoui, Fadhila</creator><creator>Ktata, Nouha</creator><creator>Maamri, Hanen</creator><creator>Baklouti, Mouna</creator><creator>Bahloul, Amine</creator><creator>Gargouri, Rania</creator><creator>Nasri, Abdennour</creator><creator>Msaad, Sameh</creator><creator>Kammoun, Samy</creator><creator>Kammoun, Samir</creator><creator>Rejab, Imen Ben</creator><creator>Charfeddine, Selma</creator><creator>Abid, Leila</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>COVID</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-1168-6450</orcidid><orcidid>https://orcid.org/0000-0002-9224-7080</orcidid></search><sort><creationdate>20220804</creationdate><title>Thromboembolic events in COVID-19 ambulatory patients: An observational study about incidence, and thromboprophylaxis outcomes</title><author>Hammami, Rania ; Jdidi, Jihen ; Chakroun, Olfa ; Issaoui, Fadhila ; Ktata, Nouha ; Maamri, Hanen ; Baklouti, Mouna ; Bahloul, Amine ; Gargouri, Rania ; Nasri, Abdennour ; Msaad, Sameh ; Kammoun, Samy ; Kammoun, Samir ; Rejab, Imen Ben ; Charfeddine, Selma ; Abid, Leila</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c669t-399054527ba84a290119e9455ae0c12dc1aa5f1f88d36c135ce3df5de300cea03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Asymptomatic</topic><topic>Blood clot</topic><topic>Body mass index</topic><topic>Cohort analysis</topic><topic>Complications</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Data collection</topic><topic>Guidelines</topic><topic>Health risks</topic><topic>Hemorrhage</topic><topic>Hospitalization</topic><topic>Hospitals</topic><topic>Illnesses</topic><topic>Medicine and Health Sciences</topic><topic>Observational studies</topic><topic>Patients</topic><topic>Polymerase chain reaction</topic><topic>Prevention</topic><topic>Prophylaxis</topic><topic>Questionnaires</topic><topic>Risk factors</topic><topic>Sea level</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Thromboembolism</topic><topic>Thrombosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hammami, Rania</creatorcontrib><creatorcontrib>Jdidi, Jihen</creatorcontrib><creatorcontrib>Chakroun, Olfa</creatorcontrib><creatorcontrib>Issaoui, Fadhila</creatorcontrib><creatorcontrib>Ktata, Nouha</creatorcontrib><creatorcontrib>Maamri, Hanen</creatorcontrib><creatorcontrib>Baklouti, Mouna</creatorcontrib><creatorcontrib>Bahloul, Amine</creatorcontrib><creatorcontrib>Gargouri, Rania</creatorcontrib><creatorcontrib>Nasri, Abdennour</creatorcontrib><creatorcontrib>Msaad, Sameh</creatorcontrib><creatorcontrib>Kammoun, Samy</creatorcontrib><creatorcontrib>Kammoun, Samir</creatorcontrib><creatorcontrib>Rejab, Imen Ben</creatorcontrib><creatorcontrib>Charfeddine, Selma</creatorcontrib><creatorcontrib>Abid, Leila</creatorcontrib><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hammami, Rania</au><au>Jdidi, Jihen</au><au>Chakroun, Olfa</au><au>Issaoui, Fadhila</au><au>Ktata, Nouha</au><au>Maamri, Hanen</au><au>Baklouti, Mouna</au><au>Bahloul, Amine</au><au>Gargouri, Rania</au><au>Nasri, Abdennour</au><au>Msaad, Sameh</au><au>Kammoun, Samy</au><au>Kammoun, Samir</au><au>Rejab, Imen Ben</au><au>Charfeddine, Selma</au><au>Abid, Leila</au><au>Ai, Tomohiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Thromboembolic events in COVID-19 ambulatory patients: An observational study about incidence, and thromboprophylaxis outcomes</atitle><jtitle>PloS one</jtitle><date>2022-08-04</date><risdate>2022</risdate><volume>17</volume><issue>8</issue><spage>e0270195</spage><epage>e0270195</epage><pages>e0270195-e0270195</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Introduction There are no clear data about the incidence and the prophylactic strategies of arterial and venous thromboembolic events (TE) in COVID-19 ambulatory patients. Thus, we conducted this study to analyze thromboembolic complications in this setting and to assess thromboprophylaxis management and outcomes in the real life. Patients and methods This is an observational study including Covid-19 ambulatory patients. We assessed incidence of venous and arterial TE events as well as thromboprophylaxis outcomes and hemorrhagic complications. We defined high risk thrombo-embolic factor according to the Belgian guidelines which are the only guidelines that described thromboprophylaxis in COVID-19 ambulatory patients. Results We included 2089 patients with a mean age of 43±16 years. The incidence of 30 days venous and arterial TE complications in our cohort was 1%. Venous thromboembolic complications occurred in 0.8% and arterial thromboembolic complications occurred in 0.3%.We noted at least one high-risk TE factor in 18.5% of patients but thromboprophylaxis was prescribed in 22.5% of the cases, LMWH in 18.1%, and Rivaroxaban in 3.7%. Hemorrhagic events occurred in eight patients (0.3%): five patients showed minor hemorrhagic events and three patients showed major ones (0.14%). Conclusions Our study showed that the incidence of thromboembolic complications is very low in COVID-19 ambulatory patients. Paradoxically, there is an over prescription of thrombo-prophylaxis in this population.</abstract><cop>San Francisco</cop><pub>Public Library of Science</pub><pmid>35925930</pmid><doi>10.1371/journal.pone.0270195</doi><tpages>e0270195</tpages><orcidid>https://orcid.org/0000-0003-1168-6450</orcidid><orcidid>https://orcid.org/0000-0002-9224-7080</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2022-08, Vol.17 (8), p.e0270195-e0270195 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2698609694 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Public Library of Science (PLoS); PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Asymptomatic Blood clot Body mass index Cohort analysis Complications Coronaviruses COVID-19 Data collection Guidelines Health risks Hemorrhage Hospitalization Hospitals Illnesses Medicine and Health Sciences Observational studies Patients Polymerase chain reaction Prevention Prophylaxis Questionnaires Risk factors Sea level Severe acute respiratory syndrome coronavirus 2 Thromboembolism Thrombosis |
| title | Thromboembolic events in COVID-19 ambulatory patients: An observational study about incidence, and thromboprophylaxis outcomes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T17%3A13%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Thromboembolic%20events%20in%20COVID-19%20ambulatory%20patients:%20An%20observational%20study%20about%20incidence,%20and%20thromboprophylaxis%20outcomes&rft.jtitle=PloS%20one&rft.au=Hammami,%20Rania&rft.date=2022-08-04&rft.volume=17&rft.issue=8&rft.spage=e0270195&rft.epage=e0270195&rft.pages=e0270195-e0270195&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0270195&rft_dat=%3Cgale_plos_%3EA712539758%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2698609694&rft_id=info:pmid/35925930&rft_galeid=A712539758&rft_doaj_id=oai_doaj_org_article_21a10e9b3ed0405cacbbaf0f53651164&rfr_iscdi=true |